Insulin resistance, blood sugar regulation, metabolic syndrome, and body composition
911 articles
Follow the fat into the liver, see how overload turns into injury and scarring, and learn why an older liver is more vulnerable and how clinicians stage and treat the disease.
Where muscle stores fat tracked insulin sensitivity, but 12-week lifestyle programs and single exercise sessions barely shifted those patterns.
Fatty liver disease affects roughly one in three adults and usually causes no symptoms. Learn how the liver ages, what MASLD is, and which habits and treatments help.
Dr. Elizabeth Kazarian discusses GLP-1 medications, brain biology, and why sustainable obesity care requires more than an injection.
Only 2 of 230 weight-loss drug trials registered reproductive outcomes, revealing an evidence gap—not proof of harm to fertility.
Adults with type 2 diabetes taking semaglutide or tirzepatide had fewer alcohol-related emergency visits than those taking SGLT2 inhibitors.
A review of 16 randomized trials (7,096 adults) finds GLP-1 and tirzepatide therapy raises GI symptoms despite diet support, while lean mass looks largely preserved.
In a 102-person phase 2 trial, a myostatin-blocking antibody cut lean mass loss on tirzepatide from 3.5 kg to 1.6 kg, with similar total weight loss.
GLP-1 drugs tracked with lower cardiovascular risk in patients with fatty liver and diabetes, but additional analyses weakened the finding.
A completed observational study explores metformin and muscle health in older adults with diabetes, but the supplied abstract reports no results.
GLP-1 drugs can strip away muscle along with fat. This review weighs bimagrumab, enobosarm and other anabolic add-ons designed to protect lean mass.
A 72-week trial found oral orforglipron reduced weight more than placebo. The highest dose did not deliver the greatest average loss.
